KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Retained Earnings (2016 - 2025)

Rigel Pharmaceuticals has reported Retained Earnings over the past 16 years, most recently at -$1.0 billion for Q4 2025.

  • For Q4 2025, Retained Earnings rose 26.4% year-over-year to -$1.0 billion; the TTM value through Dec 2025 reached -$1.0 billion, up 26.4%, while the annual FY2025 figure was -$1.0 billion, 26.4% up from the prior year.
  • Retained Earnings for Q4 2025 was -$1.0 billion at Rigel Pharmaceuticals, down from $96000.0 in the prior quarter.
  • Over five years, Retained Earnings peaked at $96000.0 in Q3 2025 and troughed at -$1.4 billion in Q3 2024.
  • A 5-year average of -$736.0 million and a median of -$1.2 billion in 2021 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: plummeted 135133000.0% in 2022 and later surged 166.67% in 2025.
  • Year by year, Retained Earnings stood at -$1.3 billion in 2021, then skyrocketed by 99.99% to -$153000.0 in 2022, then surged by 105.23% to $8000.0 in 2023, then tumbled by 17375912.5% to -$1.4 billion in 2024, then rose by 26.4% to -$1.0 billion in 2025.
  • Business Quant data shows Retained Earnings for RIGL at -$1.0 billion in Q4 2025, $96000.0 in Q3 2025, and $6000.0 in Q2 2025.